Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Roti patents



      

This page is updated frequently with new Roti-related patent applications.




Date/App# patent app List of recent Roti-related patents
07/21/16
20160208013 
 Methods and compositions for reducing cardiac damage and other conditions patent thumbnailMethods and compositions for reducing cardiac damage and other conditions
Endoglin has been identified to play a functional role as a regulator of tgfβ1 signaling, particular in tgfβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity.
Tufts Medical Center, Inc.


07/21/16
20160206709 
 Antimicrobial composition comprising pyrogenic silica and serrathopeptidase and uses thereof patent thumbnailAntimicrobial composition comprising pyrogenic silica and serrathopeptidase and uses thereof
Methods are provided for treatment of wounds using a complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Pyrogenic silica is used as a siliceous sorbent, and serrathiopeptidase as a drug..
Willingsford Limited


07/21/16
20160206591 
 Treatments for fibrotic diseases patent thumbnailTreatments for fibrotic diseases
Disclosed herein are methods for treatment for fibrosis, ocular pathologies associated with fibrosis, including proliferative vitreoretinopathy (pvr) by inhibiting the activity of activated transforming growth factor β activated kinase 1 (tak1), or activation thereof. Pharmaceutical compositions for use in the described treatments are also provided..
Mor Research Applications Ltd.


07/14/16
20160202239 
 Blood based biomarkers for diagnosing atherosclerotic coronary artery disease patent thumbnailBlood based biomarkers for diagnosing atherosclerotic coronary artery disease
The invention, in some aspects, relates to methods for evaluating a human subject for having atherosclerotic coronary artery disease (ascad) or as having a coronary atherosclerotic plaque. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling and treating atherosclerotic cad and or a coronary atherosclerotic plaque..
Global Genomics Group, Llc


07/14/16
20160200796 
 Fusion protein comprising albumin and retinol-binding protein patent thumbnailFusion protein comprising albumin and retinol-binding protein
There is provided a fusion protein comprising albumin and retinol-binding protein (rbp), which can be used for preventing or treating fibrotic diseases. The fusion protein, in which albumin and rbp are bound together, is incorporated into stellate cells and induces phenotypic reversion from myofibroblast-like cells to quiescent fat-storing phenotype.
Korea University Research And Business Foundation


07/14/16
20160199316 
 Three-layer transdermal therapy system (tts) patent thumbnailThree-layer transdermal therapy system (tts)
The invention relates to an at least three-layer transdermal therapy system (tts), which contains, in particular, rotigotine as an active ingredient. The tts comprises an active ingredient-containing central layer, which comprises at least one hygroscopic polymer or copolymer, an inner, active ingredient-permeable layer and an outer layer..
Tesa Labtec Gmbh


07/14/16
20160199127 
 Methods and apparatuses for treating auto-immune diseases by ablative neuromodulation patent thumbnailMethods and apparatuses for treating auto-immune diseases by ablative neuromodulation
The present invention, in some embodiments thereof, relates to intravascular neural ablation and, more particularly, but not exclusively, to tools and methodologies for treating systemic nerve hyperactivity through splenic and/or carotid denervation. Devices are disclosed for performing ablation and protecting a patient from formation of embolisms.
La Vita Technologies Ltd.


07/14/16
20160199091 
 Intravascular catheter balloon device having a tool for atherectomy or an incising portion for atheromatous plaque scoring patent thumbnailIntravascular catheter balloon device having a tool for atherectomy or an incising portion for atheromatous plaque scoring
An apparatus and method is disclosed for an intravascular balloon device having a balloon and a handle where a catheter tube extends between the two. The handle assembly includes an inflation device in fluid communication with the balloon.

07/14/16
20160199072 
 Bone removal under direct visualization patent thumbnailBone removal under direct visualization
An approach to removing necrotic bone under direct visualization is provided. To remove bone and to watch it being removed at the same time, one example uses an endoscope and bone removal tool assembled together by a sheath.
Smith & Nephew, Inc.


07/07/16
20160194406 
 Modulation of efferocytosis pathways for treatment of atherosclerotic disease patent thumbnailModulation of efferocytosis pathways for treatment of atherosclerotic disease
Smooth muscle cells (smc) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual..
The Board Of Trustees Of The Leland Stanford Junior University


07/07/16
20160193206 

Bet-protein-inhibiting dihydropyridopyrazinones


This invention further relates to the use of bet protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation diseases, in atherosclerotic disorders and in male fertility control.. .

06/30/16
20160185737 

N-alkoxyamide conjugates as imaging agents


The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided.

06/30/16
20160184393 

Treatment of x-linked hypohidrotic ectodermal dysplasia with a fusion eda1 protein


The invention relates to methods for the temporal administration of eda agonists, in particular edi200, which correlate to optimal therapeutic response windows required for the formation of any eda-dependent structures such as ectodermal appendages. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with genetic disorders, in particular, xlhed..

06/23/16
20160176867 

Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones


This invention further relates to the use of bet protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation diseases, in atherosclerotic disorders and in male fertility control.. .

06/16/16
20160168128 

Inhibitors of cellular necrosis and related methods


Or a pharmaceutically acceptable salt, prodrug, stereoisomer or tautomer thereof, is provided. Related compounds, methods for preparation of the same and uses of the compounds for treatment of various indications, including treatment of necrotic cell diseases and/or inflammation, are also provided..

06/16/16
20160166804 

Transcarotid neurovascular catheter


An interventional catheter for treating an artery includes an elongated body sized and shaped to be transcervically introduced into a common carotid artery at an access location in the neck. The elongated body has an overall length such that the distal most section can be positioned in an intracranial artery and at least a portion of the proximal most section is positioned in the common carotid artery during use..
Silk Road Medical, Inc.


06/16/16
20160166684 

Treatment of fibrotic diseases


The present invention relates to rspo and lgr antagonists, and methods of using the rspo and lgr antagonists for treating or preventing fibrotic diseases.. .
Oncomed Pharmaceuticals, Inc.


06/09/16
20160158502 

Methods and devices for transcarotid access


Disclosed is an arterial access sheath for introducing an interventional device into an artery. The arterial access sheath includes an elongated body sized and shaped to be transcervically introduced into a common carotid artery at an access location in the neck and an internal lumen in the elongated body having a proximal opening in a proximal region of the elongated body and a distal opening in a distal region of the elongated body.
Silk Road Medical, Inc.


06/09/16
20160158044 

Systems and methods for treating a carotid artery


Systems and methods are adapted for treating the carotid artery. The systems include interventional catheters and blood vessel access devices that are adapted for transcervical insertion into the carotid artery.
Silk Road Medical, Inc.


06/09/16
20160157826 

Non-imaging two dimensional array probe and system for automated screening of carotid stenosis


A non-imaging diagnostic ultrasound system for carotid artery diagnosis has a two dimensional array probe (10) with a low element count and relatively large element size which can cover an area of the carotid artery at its bifurcation. The elements are operated independently with no phasing, and detect doppler flow spatially beneath each element.
Koninklijke Philips N.v.


06/09/16
20160157814 

Non-imaging two dimensional array probe and system for classifying carotid stenosis


A non-imaging diagnostic ultrasound system for carotid artery diagnosis has a two dimensional array probe with a low element count and relatively large element size which can cover an area of the carotid artery at its bifurcation. The elements are operated independently with no phasing, and detect doppler flow spatially beneath each element.
Koninklijke Philips N.v.


06/02/16
20160152999 

Rhizomania-resistant gene


The present invention provides a new nucleic acid molecule which encodes a polypeptide that is able to convey a resistance to a pathogen, in particular to “beet necrotic yellow vein virus” in a plant, in particular a plant of the beta genus, in which the polypeptide is expressed, and also a preferred nucleic acid molecule encoding the rz-3 gene of beta maritima, derivatives and homologues thereof. Further aspects of the invention include vectors, transgenic plant cells, transgenic plants, methods for production thereof, and methods for identifying a resistance-conveying nucleic acid molecule..
Kws Saat Se


05/26/16
20160145294 

Antagonists of cb1 receptor


The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
Universite De Bordeaux


05/26/16
20160145177 

Method for purifying 2-fluorobutane


The present invention is a method for 2-fluorobutane to obtain highly purified 2-fluorobutane through a process comprising a step for: bringing crude 2-fluorobutane that includes 5 to 50 wt % of butene into contact with a brominating agent that can form a bromonium ion in an aprotic polar solvent in the presence of water or an alcohol having up to 4 carbon atoms; converting the butene into compounds having a boiling point higher than that of 2-fluorobutane, then recovering 2-fluorbutane from the reaction solution; and purifying the recovered 2-fluorabutane by distillation.. .
Zeon Corporation


05/26/16
20160143561 

Self-contained, portable h2/co2 (air) ratio apparatus


A self-contained, portable h2/co2 (air) ratio apparatus has an exhaled breath system, an air analyzing chamber, a hydrogen concentration analyzer, a carbon dioxide (air) concentration analyzer, an air outlet, a computational analyzer and a display unit. The display unit can be a part of the self-contained, portable h2/co2 (air) ratio apparatus, remotely a part of the self-contained, portable h2/co2 (air) ratio apparatus, or combinations thereof.
Ony, Inc.


05/19/16
20160139051 

Apparatus and distinguishing between different tissue types using specific raman spectral regions


A portable apparatus and method for distinguishing between different tissue types, such as normal tissue, necrotic tissue, and tumor tissue are provided, where the apparatus includes a housing and a plurality of raman spectrometers disposed within the housing, each spectrometer having a different spectral region. A processor is provided in communication with the plurality of spectrometers, the processor analyzing output from the plurality of spectrometers to identify the tissue type of the tissue sample.
Wayne State University


05/19/16
20160137719 

Process for producing high purity fibrinogen and thrombin for fibrin sealant


The present invention relates to a fibrin sealant kit comprising purified fibrinogen and thrombin. The invention particularly relates to an improved chromatographic process for the purification of thrombin and fibrinogen components devoid of any significant plasminogen and other impurities.
Hemarus Therapeutics Limited


05/19/16
20160136133 

Medicaments for the treatment or prevention of fibrotic diseases


R1 to r5 and x are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.. .

05/19/16
20160136107 

Storage stable transdermal patch of rotigotine


Disclosed is a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and the release liner, the adhesive layer comprising an active agent solubilized in an adhesive matrix, the adhesive matrix comprising a mixture of biocompatible polymers, wherein the active agent is soluble in at least one of the biocompatible polymers.. .
Mylan Technologies, Inc.


05/19/16
20160136001 

Sock for treatment of foot and leg wounds, methods of use and manufacture


The improved sock is made of yarns knitted into a foot and calf, with graduated compression on an individual's foot from the foot to the calf. The yarns can include wool and alpaca fibers.
Vive Wear Llc


05/19/16
20160135720 

Optical capsule and spectroscopic treating and diagnosing the intestinal tract


A device and method for mapping, diagnosing and treating disorders or other diseases, disorders or conditions (e.g., bleeding, ischemic or necrotic tissue, and presence of certain chemicals or substances) of the intestinal tract is provided using a capsule passing through the intestinal tract and sensing optical characteristics as the capsule passes through. Further, a capsule tracking system is provided for tracking a capsule's location along the length of an intestinal tract as various treatment and/or sensing modalities are employed.
Entrack, Inc.


05/12/16
20160129011 

Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines


Pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders, are described. Furthermore, the use of bet protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control is described..

05/05/16
20160122433 

Anti-pdgfr-beta antibodies and uses thereof


The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
Regeneron Pharmaceuticals, Inc.


05/05/16
20160120950 

Pharmaceutical formulations comprising incretin mimetic peptide and aprotic polar solvent


The present disclosure is directed to stable pharmaceutical formulations and uses thereof.. .
Astrazeneca Pharmaceuticals Lp


05/05/16
20160120822 

Composition containing rotigotine and use thereof and transdermal patch containing the composition


A rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in the matrix mixture system.
Jiangsu Kangbeide Pharmaceuticals Co. Ltd.


05/05/16
20160120509 

Hypodermic needle with enhanced ultrasound signature for carotid artery stenting


A hypodermic needle outer surface deflects ultrasound signals hitting the surface. The reflected signals depend on the surface which the ultrasound signal hits.

04/28/16
20160115246 

Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9


The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor.
Regeneron Pharmaceuticals, Inc.


04/28/16
20160113968 

Hypoxia-cultured mesenchymal stem cells for treating atherosclerotic lesions


A method and a pharmaceutical composition for treating an atherosclerotic lesion are provided, including administering a subject in need thereof a therapeutically effective amount of a composition comprising hypoxia-cultured mscs obtained by culturing auto- or allo-mscs under low oxygen conditions.. .
National Yang-ming University


04/28/16
20160113675 

Intravascular catheter having a cantilevered expandable incising portion


An intravascular device is provided having a catheter tube and an expandable portion including a plurality of struts supported in a cantilevered fashion so as to be splayed open when in an opened position. An incising element is provided on at least one of the struts and has a sharpened edge for creating an incision in atherosclerotic material located within a blood vessel when the expandable portion is in the opened position..

04/21/16
20160106851 

Groundbreaking platform technology for specific binding to necrotic cells


A system comprising a targeting molecule for binding necrotic cells; to the system for use as a medicament; to use of the system for diagnosis; to the system for use in treatment of diseases involving necrotic cell death, to a dosage comprising the system; to a method for determining localization of the composition within a sample using said system; and, to a method for treatment of cancers and/or diseases involving necrotic cell death using said system. In particular the invention relates to compositions targeting necrotic cells..

04/21/16
20160106811 

Method for repairing neurodegeneration


The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (afgf), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof.. .

04/14/16
20160101165 

Compositions and kits for enzymatic debridement and methods of using the same


A debridement enzyme for necrotic tissue is described that is not dependent upon proteolytic enzymatic activity but instead utilizes the amylase family of enzymes. The amylases (α-, β-, γ-amylase) are noted for the cleavage of the α-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments.

04/14/16
20160100879 

Electrical ablation devices and methods


A computer-implemented system for delivering energy to tissue having a necrotic threshold may generally comprise an electrode array comprising a plurality of electrodes, a central electrode positioned intermediate the plurality of electrodes, and a controller configured to not only apply a first sequence of electrical pulses to the electrode array to induce thermal heating in the tissue and reduce the necrotic threshold of the tissue but also apply a second sequence of electrical pulses to the central electrode to induce cell necrosis in the tissue by irreversible electroporation. Electrical ablation devices and methods of using the same are also described herein..

04/07/16
20160095876 

Composition and kits for inhibition of pathogenic microbial infection and methods of using the same


Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of an polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent..
Rochal Industries, Llp


03/31/16
20160089252 

Extravascular protective stent


An extravascular protective stent includes a booster, a hollow protective tube and a hollow separator all sequentially arranged, wherein the side wall of the protective tube is provided with a protective notch parallel to the central axis of the protective tube and extending through two ends of the protective tube. During use of the separator and the protective tube when an internal carotid artery is exposed after a common carotid artery bifurcation is separated via a submandibular incision, the separator and the protective tube wrap the internal carotid artery in sequence, allowing the separating notch and the protective notch to face outward, and the closed wall thereof to face inward and directly face the surgery direction, such that a surgeon can thoroughly excise diseased tissue in surgery and avoid hemorrhage caused by accidentally injuring the internal carotid artery during the surgery, and improve the surgical efficacy..

03/24/16
20160082264 

Implantable device including a stimulation lead for bioimpedance measurement


An implantable device includes a lead, for example for neurostimulation of the vagus nerve. The lead includes a series of stimulation electrodes and a series of external electrodes for bioimpedance measurements on blood flow located in the same region, for example on the carotid artery.
Sorin Crm Sas


03/24/16
20160082051 

Use of sea cucumber glycosaminoglycan in preparing medicine for prevention and treatment of thromboembolic disease


The present invention discloses use of sea cucumber glycosaminoglycan in the preparation of drugs. In particular, the present invention relates to use of medical use of sea cucumber glycosaminoglycan, and more particularly to use of depolymerized sea cucumber glycosaminoglycan or natural molecular segments of sea cucumber glycosaminoglycan with a weight average molecular weight greater than 54,500 da in the preparation of a drug for the prevention and treatment of thromboembolic diseases.
Heilongjiang Hongdoushan Pharmaceutical Co., Ltd.


03/24/16
20160082011 

Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome


The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.. .
Boehringer Ingelheim International Gmbh


03/24/16
20160081848 

Cooling elements with bands


A kit for cooling the blood in the carotid arteries includes a cervical immobilization collar and a cooling element. The cooling element may include a body-facing panel attached on a body-facing surface to a lining layer, an outward-facing panel, and cooling material disposed between the body-facing panel and the outward facing panel.
Cryothemic Systems, Inc.


03/24/16
20160081643 

X-ray ct device and processing method


The present invention is capable of distinguishing four types or more of substances such as air, water (soft tissues), contrast medium, and bones (calcification) to diagnose progress of atherosclerotic sites using dual energy imaging. A subject is imaged with two types of different tube voltages and an image obtained by image reconstruction is binarized to carry out a reprojection process; thereby, the distance of penetration of air is estimated, the contribution of air in measurement projection data is determined, and the amount of reduction by the air is deducted from the projection data so as to enable distinction between four or more substances such as air, water (soft tissues), contrast medium, and bones (calcification)..
Hitachi Medical Corporation


03/24/16
20160081561 

Noninvasive arterial condition detecting method, system, and non-transitory computer readable storage medium


A noninvasive arterial condition detecting system includes a processing device and an electronic stethoscope configured for auscultating carotid artery to receive sound signals. The processing device is connected to the electronic stethoscope.
National Central University


03/17/16
20160074677 

Methods and devices to modulate the autonomic nervous system via the carotid body or carotid sinus


In some embodiments, sympathetic nerves surrounding arteries or leading to organs are targeted with energy sources to correct or modulate physiologic processes. In some embodiments, different types of energy sources are utilized singly or combined with one another.
Kona Medical, Inc.


03/17/16
20160074473 

Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties


The present invention relates to peptide-phospholipid formulations, methods of generating these formulations and methods of administering these formulations for treatment. The present disclosure also provides methods for increasing cholesterol efflux, inducing anti-atherosclerotic activity, increasing pre-β hdl, inducing anti-inflammatory activity, inhibiting cytokine release (including cytokines tnf-α, il-1β, and/or il-6 or a combination thereof) and increasing cholesterol mobilization and/or esterification by administering the peptide-phospholipid formulations disclosed..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


03/17/16
20160074466 

Angiotensins for treatment of fibrosis


The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (copd), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided..
Tarix Pharmaceuticals Ltd.


03/17/16
20160074457 

Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome


Pharmaceutical/dietary supplements and food ingredient(s) derived from sphaeranthus indicus are used for controlling or treating a metabolic disorder. The supplements and food ingredient(s) are selected from sphaeranthus indicus extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof and their compositions, preferably in combination with at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from garcinia mangostana.
Laila Nutraceuticals


03/17/16
20160074422 

Mucus strengthening formulations to alter mucus barrier properties


The present technology relates to compositions and methods that strengthen mucus barriers, e.g., reduce the permeability of the mucus barriers. In some embodiments, the compositions include a model bile and a lipid mixture, wherein the model bile includes at least one salt and a lecithin.
Northeastern University


03/10/16
20160069868 

Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis


The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid targets, sirna sequences based on these targets and antibodies against the targets.
Galapagos Nv


03/10/16
20160068487 

Novel compounds as diacylglycerol acyltransferase inhibitors


This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
Glaxosmithkline Llc


03/10/16
20160068467 

Amphiphilic macromolecules and methods of use thereof


Or a salt thereof, wherein a, x, y, z and r1 have any of the values defined in the specification, and methods of use thereof. For example, certain embodiments of the invention provide a method for inhibiting atherosclerosis or atherosclerotic development in a mammal, comprising administering to the mammal an effective amount of a compound of formula (i), or a pharmaceutically acceptable salt thereof..

03/10/16
20160067247 

Novel use


The present invention is directed to compounds or pharmaceutically acceptable salts thereof for use in the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (ipf).. .
Glaxosmithkline Intellectual Property (no.2) Limited


03/03/16
20160061846 

Method for evaluating atherosclerotic lesion, and kit


The present invention provides a method and a means for evaluating atherosclerotic lesions by identifying a protein (marker protein) group, the expression level of which varies according to the progression of the atherosclerotic lesion, and using the proteins. Specifically, the present invention relates to a method for evaluating atherosclerotic lesions, comprising the steps of detecting a marker protein exhibiting an expression pattern (expression variation) characteristic at a specific disease stage of atherosclerotic lesions in a subject, and evaluating the atherosclerotic lesions in the subject based on the detection result..
National University Corporation Hokkaido University


03/03/16
20160061845 

Compositions and methods for treating steroid resistant nephrotic syndrome and/or steroid sensitive nephrotic syndrome


Disclosed are methods of determining whether a patient diagnosed with nephrotic syndrome has steroid sensitive nephrotic syndrome (ssns) or steroid resistant nephrotic syndrome (srns) by determining the levels of one or more biomarkers in a biofluid from the patient. Also disclosed are methods of treating a patient diagnosed with nephrotic syndrome, and kits and substrates related to the disclosed methods..
Children's Hospital Medical Center


03/03/16
20160060626 

Modulation of angiopoietin-like 3 expression


Provided herein are methods, compounds, and compositions for reducing expression of an angptl3 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal.
Isis Pharmaceuticals, Inc.


03/03/16
20160058368 

System and imaging biomarkers indicative of caridac thermal ablation lesions


Described here are systems and methods for visualizing thermal ablation lesions by imaging specific chemical compounds that are created during thermal ablation procedures, such as cardiac ablation procedures. When a cardiac ablation procedure is performed, a central area of coagulative necrosis is created at the treatment site.
Sunnybrook Research Institute


02/25/16
20160054304 

Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases


The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic conditions. The invention provides polypeptide and nucleic acid targets, sirna sequences based on these targets and antibodies against the targets.
Galapagos Nv


02/18/16
20160046768 

Method for preparing polyamideimide fibrid


The invention provides a method for preparing a polyamideimide fibrid, characterized by comprising the following specific steps: step 1: reacting diamine monomer with trimellitic anhydride chloride in an aprotic polar solvent in the presence of a catalyst to obtain a polyamide acid polymer, and carrying out chemical cyclization dehydration on the polyamide acid polymer to obtain a polyamideimide polymer solution; step 2: diluting the polyamideimide polymer solution, adding the diluted polyamideimide polymer solution and precipitation solution to a precipitation machine, and mixing to obtain a polyamideimide fibrid suspension; and step 3: washing, filtering and drying the polyamideimide fibrid suspension to obtain a polyamideimide fibrid. The invention is characterized by simple process, the size and shape of the fibrid are easy to be controlled, and the fibrid can be directly used to prepare high performance paper..
Jiangsu Juxian Synthetic Material Co., Ltd.


02/18/16
20160045741 

Vagus nerve and carotid baroreceptor stimulation system


Systems and methods are provided for delivering vagus nerve stimulation and carotid baroreceptor stimulation to patients for treating chronic heart failure and hypertension. The vagus nerve stimulation and carotid baroreceptor stimulation therapies may be provided using a single implantable pulse generator, which can coordinate delivery of the therapies..
Cyberonics, Inc.


02/11/16
20160039736 

Substituted aromatic compounds and related the treatment of fibrosis


Or a pharmaceutically acceptable salt thereof, wherein a is c5 alkyl, c6 alkyl, c5 alkenyl, c6 alkenyl, c(0)-(ch2)n-ch3 or ch(oh)—(ch2)n-ch3 wherein n is 3 or 4; r1 is h, f or oh; r2 is c5 alkyl, c6 alkyl, c5 alkenyl, c6 alkenyl, c(0)-(ch2)n-ch3 or ch(oh)—(ch2)n-ch3 wherein n is 3 or 4; r3 is h, f, oh or ch2ph; r4 is h, f or oh; q is 1) (ch2)mc(0)oh wherein m is 1 or 2, 2) ch(ch3)c(0)oh, 3) c(ch3)2c(0)oh, 4) ch(f)—c(0)oh, 5) cf2-c(0)oh, or 6) c(0)-c(0)oh; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.. .

02/11/16
20160038395 

Composition for facial contouring comprising mixture of botulinum toxin and air and facial contouring using the same


The present invention provides a composition for facial contouring, comprising a mixture of botulinum toxin and air, and a method of facial contouring using the same. When the mixture of botulinum toxin and air is injected into an smas layer, the mixture strengthens the smas layer and draws back the galea aponeurotica to effectively lift up the face or change the facial contour, thus effectively enhancing the effect of facial contouring..

02/04/16
20160030475 

Use of a clay product or a clay blend product to decrease the effects of bacterial disease in shrimp


Applicants have examined two clostridium species, clostridium difficile and clostridium perfringens, and found that clays can adsorb the toxin produced by both and that a clay blended product can decrease the effects of a prominent in chickens and known as necrotic enteritis, that is caused by c. Perfringens.
Oil-dri Corporation Of America


02/04/16
20160030472 

Xenon-based anesthetic gas composition usable during an endarterectomy involving the clamping of the carotid artery


A xenon-based anesthetic gas to be used, via inhalation, to maintain or preserve cerebral perfusion during an endarterectomy involving the clamping of the carotid artery in a mammal under general anesthesia. The xenon is preferably used in combination with at least one injectable anesthetic morphine agent such as remifentanil, sulfentanil, fentanyl, and alfentanil.
Air Liquide Santé (international)


02/04/16
20160030153 

Embolic protection during percutaneous heart valve replacement and similar procedures


Various devices are described to provide filtering of flow from the aorta to the left carotid artery and the right carotid artery. The filters can be brought into a desired position through one or more peripheral arteries.
Lumen Biomedical, Inc.


02/04/16
20160030001 

Helmet apparatus and system with carotid collar means on-boarded


Apparatus for helmeting with carotid collars works in conjunction with a transcranial doppler, phased array photoacoustic device to transmit a first energy to a region of interest at an internal site of a subject to produce an image and blood flow velocities of a region of interest by outputting an optical excitation energy to said region of interest and heating said region, causing a transient thermoelastic expansion and produce a wideband ultrasonic emission. Systems integrate and register the signals for use in, for example, acute stroke care..





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3531

5285

2 - 1 - 106